Novel therapeutic agents may reduce the oncogenesis of metastatic prostate cancer (IMAGE)

Elsevier

Novel therapeutic agents may reduce the oncogenesis of metastatic prostate cancer

Caption

Tumor cell properties that are most commonly affected by the inhibition of the kinase activity of cyclin-dependent kinase 19 (CDK19).

Credit

The American Journal of Pathology

Usage Restrictions

Please include attribution

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.